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Introduction
Our body detects potentially noxious 
stimuli by means of nociceptors, special-
ized neurons which translate physical or 
chemical stimuli into electrical signals and 
transmit these to the central nervous sys-
tem (CNS). The majority of these (prima-
ry) nociceptors are non-myelinated slowly 
conducting C fibers or thinly myelinated 
fast conducting Aδ fibers, the central end-
ings of which end either in the dorsal horn 
of the spinal cord or in the trigeminal nu-
cleus of the brainstem. The initial synaptic 
integration of nociceptive information oc-
curs in these structures. Some of the spi-
nal terminals of nociceptors directly stim-
ulate projection neurons in the most dor-
sal layer of the spinal cord, the lamina I, 
while other nociceptor endings activate 
excitatory or inhibitory local interneurons 
in the same lamina as well as the underly-
ing lamina II. Non-nociceptive mechano-
sensitive fibers that are activated by mild 
tactile stimuli end primarily in deep lay-
ers of the dorsal horn, where they come in 
contact with a different class of projection 
neurons, as well as with excitatory and 
inhibitory interneurons. In this way, the 
neuronal network of the dorsal horn in-
tegrates peripheral nociceptive and non-
nociceptive stimuli with pro- and antino-
ciceptive signals from pathways descend-
ing from the brainstem and midbrain in-
to the spinal cord. The result of this spinal 
processing is then transmitted via sever-
al interconnections by lamina-I projection 
neurons in lamina I to higher CNS areas, 
where nociceptive and non-nociceptive 
stimuli are consciously perceived. Neuro-
plastic changes in this network represent 
an important mechanism of chronic pain.
Synaptic plasticity in lamina-I 
projection neurons
Lamina-I projection neurons in the dor-
sal horn play a crucial role in the percep-
tion of chronic inflammatory and neuro-
pathic pain. The majority of these pro-
jection neurons are nocispecific neurons 
which, under physiological conditions, 
are activated exclusively by noxious stim-
uli. They carry neurokinin 1 (NK1) recep-
tors for the neuropeptide substance P re-
leased from peptidergic C fibers. This lat-
ter characteristic has been used to destroy 
these spinal neurons in a targeted manner. 
Animals in which a conjugate comprising 
substance P and saporin was injected in 
the spinal cord were almost completely 
protected against inflammatory and neu-
ropathic hyperalgesia [24]. Pursuing this 
idea, the plasticity of the synapses between 
primary nociceptors and these projection 
neurons have been closely investigated in 
recent years [13]. It could be demonstrated 
that intensive stimulation of these synaps-
es triggers long-term potentiation (LTP). 
In particular, synapses with neurons that 
project to the periaqueductal gray (PAG), 
undergo LTP already with stimulation fre-
quencies mimicking natural C fiber activ-
ity (. Fig. 1).
Fig. 1 8 Long-term potentiation at the synapse between primary nociceptors and nocispecific projec-
tion neurons in the lamina I. Intense stimulation of nociceptor endings leads to a persistent increase in 
synaptic transmission onto the projection neuron, as well as to hyperalgesia at the site of nociceptor 
stimulation. LI–LV indicate the various spinal laminae according to Rexed. (Modified from [13])
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Inhibitory interneurons in 
spinal control of nociception
Although homosynaptic plasticity at C-fi-
ber synapses is able to explain increased 
pain perception at the site of nociceptor 
stimulation (i.e., primary hyperalgesia), it 
is not able to simply explain why sensitiza-
tion to signals from unconditioned inputs 
also occurs. Indeed, local C-fiber stimu-
lation—experimentally inducible by, e.g., 
injection of capsaicin, a selective activa-
tor of nociceptors—also leads to hyper-
sensitivity in unconditioned neighboring 
tissue and to pain originating from stim-
ulation of non-nociceptive (capsaicin-in-
sensitive) fibers (secondary hyperalge-
sia, . Fig. 2). Interestingly, this second-
ary hyperplasia involves exclusively me-
chanical stimuli, while thermal sensitivi-
ty remains unaltered. This mechanical hy-
persensitivity is not based on the sensiti-
zation of peripheral nerve fibers, but rath-
er is the result of altered central process-
ing of sensory signals. Thus this second-
ary hyperplasia resembles heterosynaptic 
plasticity: intense stimulation of nocicep-
tive C fibers leads to the sensitization of 
the body to signals from other uncondi-
tioned fibers. Detailed analysis has shown 
that, at least in part, these fibers are low-
threshold mechanosensitive fibers, i.e., 
not nociceptors. Sensitization to signals 
from these fibers leads to the painful per-
ception of normally painless, mild tactile 
stimuli, called allodynia. Neurophysiolog-
ically, this phenomenon is explained by 
the fact that signals from non-nociceptive 
fibers lead to the excitation of pain-sig-
naling neurons. This unphysiological ex-
citation of normally nocispecific projec-
tion neurons could be the result of gen-
erally increased projection neuron excit-
ability. Alternatively, secondary hyperal-
gesia and allodynia could also be the result 
of reduced inhibitory control in the dorsal 
horn. A popular model to explain allodyn-
ia assumes the existence of two normally 
separate pathways for the spinal transmis-
sion of nociceptive and non-nociceptive 
stimuli. While nocispecific neurons are 
excited exclusively by nociceptive fibers 
(marked with“N” in . Fig. 2), so-called 
wide dynamic range (WDR) neurons are 
excited by both nociceptive and non-no-
ciceptive fibers. GABAergic and glyciner-
gic neurons keep both pathways function-
ally separate in vivo. A critical role of this 
kind played by inhibitory interneurons in 
the superficial dorsal horn was already 
proposed more than 45 years in the“gate 
control” theory of pain [18] (. Fig. 2a). 
Indeed, inhibitory γ-aminobutyric acid-
releasing (GABAergic) and glycinergic 
neurons are densely packed in the super-
ficial dorsal horn (. Fig. 2b). Both neu-
Fig. 2 8 a Primary and secondary hyperalgesia. In addition to sensitization 
at the site of nociceptor stimulation (primary hyperalgesia, dark red area), 
hypersensitivity to signals from non-nociceptive fibers also occurs in neigh-
boring unconditioned areas (secondary hyperalgesia, light red area). Under 
physiological conditions, nociceptor signals are transmitted via nocispecific 
neurons (N) to supraspinal centers, while non-nociceptive signals are trans-
mitted via wide dynamic range neurons in the deep dorsal horn. Left“Gate 
control” theory of pain (modified according to [18]). Inhibitory interneu-
rons in the superficial dorsal horn, the substantia gelatinosa (SG), deter-
mine whether signals are transmitted through the spinal transmission sys-
tem (T) to the brain. The activity of these inhibitory interneurons is inversely 
regulated by nociceptors and non-nociceptive fibers. b GABAergic and gly-
cinergic interneurons, visualized here by cell type-specific expression of en-
hanced green fluorescent protein (EGFP), are abundant in the superficial 
dorsal horn. c Both transmitters open chloride channels (GABAA and strych-
nine-sensitive glycine receptors), which inhibit the activation of postsynap-
tic neurons
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rotransmitters inhibit the excitability of 
spinal neurons by opening chloride chan-
nels (. Fig. 2c). In vivo pharmacological 
blockade of spinal glycine or GABAA re-
ceptors leads to symptoms similar to sec-
ondary hyperalgesia [27]. On a cellular 
level reduced inhibition demasks polysyn-
aptic signals from non-nociceptive fibers 
occurs in previously nocispecific neurons 
[3, 29]. These findings show that non-no-
ciceptive fibers are connected with nor-
mally nocispecific neurons by excitatory 
interneurons, and that these connections 
are masked by inhibitory neurons un-
der physiological conditions. Moreover, 
GABA and glycine receptor blockade in-
creases the response of lamina I neurons 
to C-fiber stimulation and induces spon-
taneous epilepsy-like discharge patterns 
in these neurons. In the intact organism, 
such cellular changes lead to correspond-
ing sensory changes. Injecting GABAA or 
glycine receptor blockers induces hyper-
sensitivity to noxious stimuli (hyperalge-
sia), nociceptive reactions following stim-
ulation of non-nociceptive fibers (allo-
dynia), and behavioral changes suggestive 
of spontaneous pain. Reducing GABAer-
gic or glycinergic inhibition thus recapit-
ulates important characteristics of patho-
logical pain.
Endogenous mechanisms 
of disinhibition
Investigations carried out in recent years 
by various groups have shown that loss 
of spinal inhibitory control subsequent to 
peripheral inflammation, or neuropathies, 
or following intensive stimulation of noci-
ceptors manifests itself endogenously.
Disinhibition in inflammation
In the context of inflammatory reactions, 
increased production of pronociceptive 
prostaglandins, in particular of prosta-
glandin E2 (PGE2), is seen in peripher-
al inflamed tissue, but also in the CNS. 
Induction of cyclooxygenase-2 (COX-
2), a key enzyme in prostaglandin syn-
thesis, is a key process. On a cellular lev-
el, PGE2 production results in facilitated 
transmission of signals from sensory af-
ferents to second order neurons in the 
superficial dorsal [20], in direct depo-
larization of neurons in the deep dorsal 
horn [2], as well as in specific inhibition 
of glycine receptors in the superficial lay-
ers of the dorsal horn, i.e., in the central 
nociceptive innervation territories [34] 
(. Fig. 3). PGE2 produced in the spinal 
cord activates PGE2 receptors of the EP2 
subtype, leading to increased production 
of cAMP as well as protein kinase A stim-
ulation [1]. This activation leads in turn to 
phosphorylation and inhibition of a par-
ticular isoform of glycine receptors con-
taining the α3 subunit (GlyRα3 receptors) 
[9]. The contribution of this process to 
pain sensitization in the context of various 
pathologies has been investigated with the 
help of genetically manipulated mice lack-
ing individual elements of this transduc-
tion cascade. EP2 receptor- and GlyRα3-
deficient mice demonstrated an almost 
complete absence of nociceptive sensiti-
zation following spinal PGE2 injection. 
Moreover, they recover far more rapidly 
from inflammation-induced pain sensiti-
zation than wild-type mice [1, 9, 33]. Fur-
ther findings support the relevance of this 
prostaglandin-mediated disinhibition in 
inflammation-induced pain sensitization. 
Thus, mice lacking the catalytic subunit 
of neuronal protein kinase A also showed 
decreased pain sensitization by spinally 
injected PGE2 [16]. Conditional COX-2-
deficient mice lacking COX-2 specifically 
in the nervous system did not develop me-
chanical pain sensitization following pe-
ripheral inflammation [31]. Interestingly, 
EP2- and GlyRα3-deficient mice showed 
no changes in pain reactions in a series 
of other pain models. In particular, pain 
sensitization remained unchanged follow-
ing peripheral nerve injury and chemical 
stimulation of nociceptors using capsaicin 
or formalin [10, 12].
Disinhibition following 
nociceptor stimulation
Loss of inhibitory spinal pain control al-
so plays an important role in neuropath-
ic pain and in pure activity-related forms 
of pain sensitization. As discussed above, 
intense stimulation of nociceptors causes 
not only nociceptive sensitization at the 
site of stimulation (primary hyperalge-
sia), but also in surrounding non-stimu-
lated areas (secondary hyperalgesia, [19]). 
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Neuroplastic changes play an important role 
in the generation and maintenance of chron-
ic pain syndromes. Such changes occur at all 
levels of the neuraxis, from the peripheral ter-
minals of primary sensory neurons to the ce-
rebral cortex. Changes observed in the spi-
nal dorsal horn in particular provide a mech-
anistic basis for many of the characteristics 
of chronic pain syndromes. While facilitated 
synaptic transmission between nociceptive 
fibers and spinal projection neurons contrib-
utes to enhanced perception of noxious stim-
uli (hyperalgesia), diminished function of GA-
BAergic and glycinergic interneurons not on-
ly induces hyperalgesia, but also triggers no-
ciceptive reactions on exposure to innocuous 
stimuli and spontaneous pain behavior in the 
absence of any sensory stimulation. Spinal 
disinhibition thus recapitulates typical symp-
toms of chronic pathological pain syndromes. 
Studies performed by various groups over 
the last 10 years demonstrate that such spi-
nal disinhibition occurs naturally in response 
to peripheral inflammation and nerve dam-
age. The present article summarizes current 
status of this research.
Keywords
Spinal cord · Pain · GABA · Glycine ·  
Somatosensory processing
37e-Neuroforum 2 · 2011  | 
If one assumes that this activity- and C fi-
ber-dependent form of secondary hyper-
algesia also depends on disinhibition, in-
tense spinal glutamate release from noci-
ceptors should result in reduced synaptic 
inhibition by glycine or GABA. Hetero-
synaptic plasticity of this kind requires the 
existence of a diffusible messenger that 
transmits the information from nocicep-
tive excitatory synapses to inhibitory syn-
apses. Endocannabinoids and CB1 canna-
binoid receptors couple intense glutama-
tergic excitation to diminished inhibition 
in numerous CNS regions [5]. The activa-
tion of CB1 receptors leads to reduced gly-
cine and GABA release also in the dorsal 
horn of the spinal cord (. Fig. 4). Mice 
lacking CB1 receptors, either globally or 
specifically from inhibitory dorsal horn 
neurons, are largely protected from cap-
saicin-induced mechanical pain sensiti-
zation [25]. Spinally injected CB1 recep-
tor antagonists or group I metabotropic 
glutamate receptor antagonists can re-
verse secondary hyperalgesia in animal 
models. The pronociceptive effect of en-
docannabinoids produced in the spinal 
cord appears surprising at first glance giv-
en the many reports on the analgesic ac-
tion of cannabinoids. However, it must 
be borne in mind that the reduced pain 
sensitivity in CB1 receptor-deficient mice 
and the analgesic action of CB1 receptor 
antagonists is limited to activity-depen-
dent pain sensitization and has not been 
observed in inflammatory or neuropath-
ic pain models. This is supported by find-
ings from acute human pain models [15, 
22], as well as from clinical studies in post-
operative pain patients. In these settings, 
cannabinoids not only failed to show an 
analgesic effect, but instead resulted in in-
creased pain. The fact that CB1 receptor 
agonists relieve pain in chronic pain pa-
tients could therefore mean that purely ac-
tivity-dependent mechanisms of second-
ary hyperalgesia play only a minor role in 
chronic pain.
Disinhibition following 
peripheral nerve injury
A third form of pathological pain sensiti-
zation occurs following damage to the pe-
ripheral or central nervous system. In an 
experimental setting, neuropathic pain is 
usually evoked through mechanical le-
sion (ligature or partial transsection) of 
the sciatic nerve. This elicits sensitization 
of the affected extremity to thermal and 
mechanical stimuli, persisting over sever-
al weeks. In recent years, it has been ob-
served that microglial cells play a cru-
cial role in neuropathic pain sensitization 
(. Fig. 5). Following peripheral nerve le-
sion, these cells are recruited in a multi-
stage process in the spinal innervation ar-
ea of the injured nerve fibers. After neu-
ronal damage, primary sensory fibers re-
lease the cytokine CCL2 (also known as 
macrophage chemoattractant protein-1, 
MCP-1), which binds to CCR2 receptors 
on microglial cells [28, 36]. Further mi-
croglial activation depends on puriner-
gic signals, which arise from increased 
expression of ionotropic P2X4 receptors 
on microglial cells. In order to cause pain 
sensitization, microglial activation must 
lead ultimately to altered neuronal com-
munication. This task is fulfilled by brain-
derived neurotrophic factor (BDNF), the 
production and release of which is trig-
gered by activation of P2X4 receptors, mi-
croglial calcium signals and subsequent 
activation of the p38 MAP kinase signal-
ing pathway [8]. BDNF binds to neuro-
nal trk-B receptors and leads to increased 
expression of the potassium-chloride ex-
porter KCC2 [7]. KCC2 keeps the intra-
cellular chloride concentration in neu-
Fig. 3 8 Spinal disinhibition as a result of peripheral inflammation. a Strychnine-sensitive (inhibitory) glycine receptors are 
abundant in the dorsal horn. Those containing the α3 subunit are specifically concentrated in the superficial layers where no-
ciceptor endings also lie. Activation of EP2 receptors by PGE2 inhibits this glycine receptor subtype specifically via protein ki-
nase A-dependent phosphorylation. b In mice lacking the EP2 receptor or Glyα3 subunit, no reduction in glycinergic inhibi-
tion by PGE2 takes place. c These mice recover much faster from inflammatory hyperalgesia than wild-type mice. (a,b Modi-
fied according to [9]; c modified according to [33])
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rons low, thus enabling the hyperpolar-
izing action of GABA and glycine. Con-
versely, reduced KCC2 expression results 
in an increase in the intracellular chlo-
ride concentration and reduced inhibi-
tion by GABA and glycine. In extreme 
cases, GABAergic and glycinergic inhi-
bition can even be reversed into depolar-
ization and excitation. Neurons in the su-
perficial dorsal horn, which have only a 
relatively low chloride extrusion capaci-
ty, appear to be most susceptible to these 
changes [6]. The question of whether GA-
BA indeed acquires an excitatory effect or 
whether its inhibitory action is merely re-
duced is important for possible therapeu-
tic implications. The majority of publica-
tions report that a local increase in GA-
BAergic transmission mitigates neuro-
pathic pain [14, 35]. It is difficult to rec-
oncile this finding with an excitatory ef-
fect of GABA, suggesting rather that the 
inhibitory action of GABA and glycine is 
reduced but not changed into one of exci-
tation. Alternatively, the analgesic effect of 
enhanced GABAergic transmission may 
result from an increase in shunting con-
ductance.
Implications for the 
treatment of chronic pain
The findings discussed above demon-
strate that pain pathologies of varying or-
igin converge on a reduction of inhibito-
ry pain control in the spinal cord. Phar-
macologically increased GABAergic and 
glycinergic inhibition in the dorsal horn 
may therefore represent a new rational ap-
proach to the treatment of chronic pain, 
which should be equally effective irre-
spective of the contribution of inflamma-
tory or neuropathic components. Indeed, 
increased synaptic inhibition by GABAA 
receptor modulators has a marked anti-
hyperalgesic effect in inflammatory and 
neuropathic pain sensitization [35]. Inves-
tigations in GABAA receptor mutant mice 
show that these desired spinal effects are 
based on the activation of specific GABAA 
receptor subtypes containing the α2 and/
or α3 subunit [14]. This specificity could 
prove crucial for the development of new 
pharmaceuticals, since the typical unde-
sired effects of classic benzodiazepines 
(sedation, cognitive dysfunction, and ad-
diction) require α1-GABAA receptor ac-
tivation. At least in animal models, sub-
type-selective activators of GABAA recep-
tors have shown the desired antihyper-
analgesic action, while undesired effects 
have been hitherto less pronounced [35]. 
In this context, increasing glyciner-
gic inhibition pharmacologically could 
also prove to be very interesting. Cur-
rently, there are no compounds available 
which would do for glycine receptors what 
benzodiazepines do for GABAA recep-
tors. However, glycine receptors still car-
ry binding sites for allosteric modulators 
such as various cannabinoids [11]. Recent 
results even suggest that at least part of the 
analgesic action of cannabis (tetrahydro-
cannabinol, THC) is based on direct inter-
action with spinal glycine receptors [32].
A model of neuronal connectivity
A mechanistic understanding of the de-
velopment of secondary hyperalgesia and 
Fig. 4 7 Activation of can-
nabinoid CB1 receptors 
by the cannabinoid recep-
tor agonists WIN 55,212-2 
(WIN) results in reduced re-
lease of GABA and glycine, 
while glutamate release 
from excitatory spinal inter-
neurons remains unaltered. 
Inhibition of GABA and gly-
cine release by WIN 55,212-
2 is reversed by the CB1 re-
ceptor antagonist AM251. 
Intense glutamate release 
from nociceptors induces 
the production and release 
of endocannabinoids and 
could thus link intense no-
ciceptor stimulation to re-
duced synaptic inhibition. 
Endocannabinoids and CB1 
receptors are thus able to 
function as mediators of 
secondary C fiber-transmit-
ted hyperalgesia. (Modified 
according to [25])
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allodynia crucially depends on identifying 
the relevant sensory nerve fibers and spi-
nal (inter-) neurons, as well as on accurate 
knowledge of their connectivity. Although 
we are still far from seeing the full picture, 
interesting observations have been made 
in sub-fields in recent years. Thus, a hith-
erto unknown fiber class could be identi-
fied which, when activated, leads to abnor-
mal pain sensation in secondary hyperal-
gesic/allodynic areas. This class represents 
a subpopulation of non-myelinated, low-
threshold mechanosensitive fibers charac-
terized by the expression of a certain ve-
sicular glutamate transporter (VGluT3) 
and the absence of typical characteristic 
peptidergic and non-peptidergic nocicep-
tors [4]. The vast majority of these neu-
rons bind neither isolectin B4 (IB4) nor 
antibodies to calcitonin gene-related pep-
tide (CGRP), two classical markers of pri-
mary nociceptors. VGluT3-deficient mice 
showed markedly reduced secondary hy-
peralgesia following subcutaneous capsa-
icin injection, as well as reduced mechani-
cal sensitization in the presence of inflam-
mation, peripheral nerve lesion, or follow-
ing cutaneous injury. These fibers termi-
nate in the spinal cord in the lamina I and 
at the border between lamina II and III, in 
the immediate vicinity of protein kinase 
Cγ (PKCγ)-expressing neurons. These 
neurons are excitatory interneurons sit-
uated at the border between innervation 
regions of nociceptive and non-nocicep-
tive fibers [23, 26]. Remarkably, PKCγ-
deficient mice demonstrated strongly re-
duced hyperalgesia following peripheral 
nerve lesion and inflammation [17]. More-
over, blockade of PKCγ also prevents gly-
cine receptor blockade-induced mechan-
ical hyperalgesia. Experiments in which 
neuronal activation was demonstrated by 
c-fos expression also showed that PKCγ-
positive neurons are activated by non-no-
ciceptive but not by nociceptive fibers. 
Although not unequivocally proven to 
date, it is likely that PKCγ-positive neu-
rons project via polysynaptic connections 
to normally nocispecific neurons. Inter-
neurons with dendritic trees extending in 
a stellate formation (stellate cells) in the 
superficial posterior horn are possibly in-
terconnected between VGlut3-positive fi-
bers and PKCγ-positive neurons. The na-
ture of the inhibitory neurons controlling 
this circuit is even less well understood. 
Functional neurobiological methods de-
veloped recently, such as targeted stimu-
lation of defined neuronal populations by 
light-activated ion channels (channel rho-
dopsins) or their targeted destruction us-
ing cell-specific toxins, promise to provide 
new insights into this exciting field of re-
search.
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Fig. 5 8 The role of microglia in the development of hyperalgesia following peripheral nerve lesion. 
A central neuron is shown (middle) in the superficial dorsal horn, which receives synaptic signals from 
a damaged sensory fiber (left) and an inhibitory interneuron (right). Microglial cells (bottom) repre-
sent the functional connection between damaged nerve fibers and reduced synaptic inhibition. Fol-
lowing peripheral nerve lesion, the chemokine CCL2 is released from the endings of sensory nerve fi-
bers. CCL2 recruits spinal microglia via activation of CCR2 receptors, additionally leading to increased 
expression of purinergic P2X2 receptors. Stimulation of the latter by ATP in turn induces the produc-
tion and release of BDNF via a p38 MAP kinase-dependent process. BDNF then binds to trkB receptors 
on neurons in the dorsal horn, leading to reduced expression of the chloride exporter KCC2, which ul-
timately results in an increase in the intracellular chloride concentration and attenuated GABAergic 
and glycinergic inhibition. In this way, BDNF connects microglial activation with reduced synaptic inhi-
bition in the dorsal horn
40 |  e-Neuroforum 2 · 2011
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